Radiation and New Medications Before and After Lung Cancer Surgery

This trial is testing a new combination approach for people with stage II or IIIA non-small cell lung cancer. You would receive radiation therapy over three days, followed by two medications called tislelizumab and anlotinib given together before surgery, then continue taking these medications for one year after surgery. The goal is to see if this combination approach helps improve survival and reduces the cancer's ability to return.

For people with earlier-stage lung cancer, current treatments don't always prevent cancer from returning. This trial is exploring whether combining radiation therapy with these two medications before and after surgery might work better than standard approaches alone.